GLAXOSMITHKLINE has
announced that Benlysta
(belimumab) has now been
approved for marketing in Australia
as an add-on therapy in adult
patients with active, autoantibodypositive
systemic lupus
erythematosus (SLE) with a high
degree of disease activity despite
standard therapy.
CLICK HERE for more information
on the approval.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jul 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.